T. Harris

Association between Objectively Measured Physical Activity and Mortality in NHANES.

D. Berrigan, V. Zipunnikov, A. Koster, 2016, Medicine & Science in Sports & Exercise.

Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema.

R. Stockley, T. Harris, C. Llewellyn-Jones, 1996, American journal of respiratory and critical care medicine.

A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation

P. Swinburn, P. Plaschke, N. Ringdal, 1996, Mediators of inflammation.

Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study.

R. D. du Bois, A. Southcott, T. Harris, 1999, The European respiratory journal.

Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr.

F. Bonifazi, T. Harris, J. V. van Helmond, 1996, Respiratory medicine.

High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group.

E. Bateman, J. Ayres, J. Ayres, 1995, The European respiratory journal.

Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less.

T. Harris, C. Hallett, T. A. Harris, 1998, Respiratory medicine.

Association between Objectively Measured Physical Activity and Mortality in NHANES.

D. Berrigan, V. Zipunnikov, A. Koster, 2016, Medicine and science in sports and exercise.